Evaluation of classical clinical endpoints as surrogates for overall survival in patients treated with immune checkpoint blockers: a systematic review and meta-analysis
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Cancer Research and Clinical Oncology"
DOI: 10.1007/s00432-018-2738-x
Abstract: PurposeClassical clinical endpoints [e.g., objective response rate (ORR), disease control rate (DCR), and progression-free survival (PFS)] may not be appropriate for immune checkpoint blockers (ICBs). We evaluated correlations between these endpoints and overall survival (OS)… read more here.
Keywords: single agent; analysis; rate; month pfs ... See more keywords
Development and validation of a host-dependent, PDL1-independent, biomarker to predict 6-month progression-free survival in metastatic non-small cell lung cancer (mNSCLC) patients treated with anti-PD1 immune checkpoint inhibitors (ICI) in the CERTIM Cohort: The ELY study.
Sign Up to like & getrecommendations! Published in 2021 at "EBioMedicine"
DOI: 10.1016/j.ebiom.2021.103630
Abstract: BACKGROUND Immune checkpoint inhibitors (ICI) are dramatically active in a minority of non-small cell lung cancer (NSCLC) patients. We studied here the relationship between patients's metabolism and outcome under ICI. METHODS Metastatic NSCLC patients underwent… read more here.
Keywords: immune checkpoint; checkpoint inhibitors; cohort; month pfs ... See more keywords